Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan Safety Study in Metastatic Hormone-Resistant Prostate Cancer
NCT01000948Phase 2Terminated
- Sponsor
- Aarhus University Hospital
- Start
- Oct 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zibotentan in prostate cancer (PCa), sponsored by Aarhus University Hospital. Primary endpoint: Safety and tolerability profile at 2 years. Started Oct 2009; status: terminated.
02
Drugs
zibotentan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01000948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000948.